PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...
Explore the latest oncology biotech news, from clinical data to fundraising and biotech deals, in our September 2026 roundup.
Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...
Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.
Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.
Meet Spain's biotech ecosystem at BIOSPAIN 2026 in Bilbao. Now annual, the event draws 1,000+ companies and participants from 30+ countries.
Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification.
For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results